8380 Federal Register / Vol. 86, No. 23 / Friday, February 5, 2021 / Notices 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), as 

amended in 85 FR 15798 (March 19, 

2020), such responses will be 

considered by the Commission if 

received not later than 20 days after the 

date of service by the complainants of 

the complaint and the notice of 

investigation. Extensions of time for 

submitting responses to the complaint 

and the notice of investigation will not 

be granted unless good cause therefor is 

shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: February 1, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–02376 Filed 2–4–21; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

Notice of Receipt of Complaint; 

Solicitation of Comments Relating to 

the Public Interest 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has received a complaint 

entitled Certain LTE-Compliant Cellular 

Communication Devices, DN 3531; the 

Commission is soliciting comments on 

any public interest issues raised by the 

complaint or complainant’s filing 

pursuant to the Commission’s Rules of 

Practice and Procedure. 

FOR FURTHER INFORMATION CONTACT: Lisa 

R. Barton, Secretary to the Commission, 

U.S. International Trade Commission, 

500 E Street SW, Washington, DC 

20436, telephone (202) 205–2000. The 

public version of the complaint can be 

accessed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

For help accessing EDIS, please email 

EDIS3Help@usitc.gov. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server at United 

States International Trade Commission 

(USITC) at https://www.usitc.gov. The 

public record for this investigation may 

be viewed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission has received a complaint 

and a submission pursuant to § 210.8(b) 

of the Commission’s Rules of Practice 

and Procedure filed on behalf of 

Evolved Wireless, LLC on February 1, 

2021. The complaint alleges violations 

of section 337 of the Tariff Act of 1930 

(19 U.S.C. 1337) in the importation into 

the United States, the sale for 

importation, and the sale within the 

United States after importation of 

certain LTE-compliant cellular 

communication devices. The 

complainant names as respondents: 

Samsung Electronics Co., Ltd. of South 

Korea; Samsung Electronics America, 

Inc. of Ridgefield Park, NJ; and Motorola 

Mobility LLC of Chicago, IL. The 

complainant requests that the 

Commission issue a limited exclusion 

order, cease and desist orders, and 

impose a bond upon respondents’ 

alleged infringing articles during the 60- 

day Presidential review period pursuant 

to 19 U.S.C. 1337(j). 

Proposed respondents, other 

interested parties, and members of the 

public are invited to file comments on 

any public interest issues raised by the 

complaint or § 210.8(b) filing. 

Comments should address whether 

issuance of the relief specifically 

requested by the complainant in this 

investigation would affect the public 

health and welfare in the United States, 

competitive conditions in the United 

States economy, the production of like 

or directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) Explain how the articles 

potentially subject to the requested 

remedial orders are used in the United 

States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the requested remedial 

orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or third 

party suppliers have the capacity to 

replace the volume of articles 

potentially subject to the requested 

exclusion order and/or a cease and 

desist order within a commercially 

reasonable time; and 

(v) explain how the requested 

remedial orders would impact United 

States consumers. 

Written submissions on the public 

interest must be filed no later than by 

close of business, eight calendar days 

after the date of publication of this 

notice in the Federal Register. There 

will be further opportunities for 

comment on the public interest after the 

issuance of any final initial 

determination in this investigation. Any 

written submissions on other issues 

must also be filed by no later than the 

close of business, eight calendar days 

after publication of this notice in the 

Federal Register. Complainant may file 

replies to any written submissions no 

later than three calendar days after the 

date on which any initial submissions 

were due. Any submissions and replies 

filed in response to this Notice are 

limited to five (5) pages in length, 

inclusive of attachments. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. Submissions should refer 

to the docket number (‘‘Docket No. 

3531’’) in a prominent place on the 

cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, Electronic Filing 

Procedures 1). Please note the 

Secretary’s Office will accept only 

electronic filings during this time. 

Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov.) No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. Persons with questions 

regarding filing should contact the 

Secretary at EDIS3Help@usitc.gov. 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 23 / Friday, February 5, 2021 / Notices 8381 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: February 1, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–02435 Filed 2–4–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–772] 

Bulk Manufacturer of Controlled 

Substances Application: Sterling 

Pharma USA, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Sterling Pharma USA LLC has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 6, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 6, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on January 5, 2021, 

Sterling Pharma USA, LLC., 1001 

Sheldon Drive, Suite 101, Cary, North 

Carolina 27513–2078, applied to be 

registered as an bulk manufacturer of 

the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Tetrahydrocannabinols ............... 7370 I 

The company plans to manufacture in 

bulk drug code 7370 

(Tetrahydrocannabinols) exclusively 

from hemp extract, for distribution and 

sale to its customers. No other activity 

for this drug code is authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–02455 Filed 2–4–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–771] 

Bulk Manufacturer of Controlled 

Substances Application: Noramco, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Noramco Inc has applied to 

be registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 6, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 6, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 3, 2020, 

Noramco Inc, 1550 Olympic Drive, 

Athens Georgia 30601, applied to be 

registered as an bulk manufacturer of 

the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric Acid .... 2010 I 

Marihuana Extract ..................... 7350 I 

Marihuana ................................. 7360 I 

Tetrahydrocannabinols ............. 7370 I 

Codeine-N-oxide ....................... 9053 I 

Dihydromorphine ....................... 9145 I 

Hydromorphinol ......................... 9301 I 

Nabilone .................................... 7379 II 

Codeine ..................................... 9050 II 

Dihydrocodeine ......................... 9120 II 

Oxycodone ................................ 9143 II 

Hydromorphone ........................ 9150 II 

Hydrocodone ............................. 9193 II 

Levorphanol .............................. 9220 II 

Morphine ................................... 9300 II 

The company plans to manufacture 

bulk active pharmaceutical ingredients 

(API) and reference standards for 

distribution to their customers. 

In reference to drug codes 7350 

(Marihuana Extract), 7360 (Marihuana), 

and 7370 (Tetrahydrocannabinols), the 

company plans to bulk manufacture 

these drugs as synthetics. No other 

activities for these drugs are authorized 

for this registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–02454 Filed 2–4–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

[OMB Number 1125–NEW] 

Agency Information Collection 

Activities; Proposed Collection; 

Comments Requested; FOIAXpress/ 

FOIA Public Access Link 

AGENCY: Executive Office for 

Immigration Review, Department of 

Justice. 

ACTION: 30-day notice. 

SUMMARY: The Department of Justice 

(DOJ), Executive Office for Immigration 

Review (EOIR), will be submitting the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. 


jbell on DSKJLSW7X2PROD with NOTICES